 2021 Q3 Earnings Call Summary

LabCorp reported strong Q3 results with revenue of $4.1 billion, adjusted EPS of $6.82, and free cash flow of $650 million. The company's Diagnostics and Drug Development businesses performed well, with 10% and 22% growth, respectively. COVID testing volumes were above the same period last year, with an average of 85,000 tests per day. The company continues to invest in new innovations, including a combined COVID and flu-at-home collection kit and collaborations with AstraZeneca and Merck. The company is also working to address health equity issues and has partnered with the Community Clinical Oncology Research Network. The company expects to drive continued profitable growth in its Base Business, while COVID testing volumes are expected to decline through the remainder of the year.